Han, S.; Lim, J.Y.; Cho, K.; Lee, H.W.; Park, J.Y.; Ro, S.W.; Kim, K.S.; Seo, H.R.; Kim, D.Y.
Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). Cancers 2022, 14, 2733.
https://doi.org/10.3390/cancers14112733
AMA Style
Han S, Lim JY, Cho K, Lee HW, Park JY, Ro SW, Kim KS, Seo HR, Kim DY.
Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). Cancers. 2022; 14(11):2733.
https://doi.org/10.3390/cancers14112733
Chicago/Turabian Style
Han, Sojung, Ji Yeon Lim, Kyungjoo Cho, Hye Won Lee, Jun Yong Park, Simon Weonsang Ro, Kyung Sik Kim, Haeng Ran Seo, and Do Young Kim.
2022. "Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)" Cancers 14, no. 11: 2733.
https://doi.org/10.3390/cancers14112733
APA Style
Han, S., Lim, J. Y., Cho, K., Lee, H. W., Park, J. Y., Ro, S. W., Kim, K. S., Seo, H. R., & Kim, D. Y.
(2022). Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). Cancers, 14(11), 2733.
https://doi.org/10.3390/cancers14112733